200 related articles for article (PubMed ID: 17516395)
1. Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus.
Mohr JF; Murray BE
Clin Infect Dis; 2007 Jun; 44(12):1536-42. PubMed ID: 17516395
[TBL] [Abstract][Full Text] [Related]
2. Counterpoint: Vancomycin and Staphylococcus aureus--an antibiotic enters obsolescence.
Deresinski S
Clin Infect Dis; 2007 Jun; 44(12):1543-8. PubMed ID: 17516396
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
[TBL] [Abstract][Full Text] [Related]
4. Is vancomycin obsolete?
Legendre D
Am J Health Syst Pharm; 2009 Jun; 66(11):977-8. PubMed ID: 19451604
[No Abstract] [Full Text] [Related]
5. Growing Resistance to Vancomycin among Methicillin Resistant Staphylococcus Aureus Isolates from Different Clinical Samples.
Pahadi PC; Shrestha UT; Adhikari N; Shah PK; Amatya R
JNMA J Nepal Med Assoc; 2014; 52(196):977-81. PubMed ID: 26982895
[TBL] [Abstract][Full Text] [Related]
6. Monitoring of vancomycin serum levels for the treatment of staphylococcal infections.
Kitzis MD; Goldstein FW
Clin Microbiol Infect; 2006 Jan; 12(1):92-5. PubMed ID: 16460555
[TBL] [Abstract][Full Text] [Related]
7. Vancomycin: does it still have a role as an antistaphylococcal agent?
Deresinski S
Expert Rev Anti Infect Ther; 2007 Jun; 5(3):393-401. PubMed ID: 17547504
[TBL] [Abstract][Full Text] [Related]
8. Exploration of optimal dosing regimens of vancomycin in patients infected with methicillin-resistant Staphylococcus aureus by modeling and simulation.
Lim HS; Chong YP; Noh YH; Jung JA; Kim YS
J Clin Pharm Ther; 2014 Apr; 39(2):196-203. PubMed ID: 24428720
[TBL] [Abstract][Full Text] [Related]
9. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains.
Sakoulas G; Moellering RC
Clin Infect Dis; 2008 Jun; 46 Suppl 5():S360-7. PubMed ID: 18462091
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo activities of echinomycin against clinical isolates of Staphylococcus aureus.
Park YS; Shin WS; Kim SK
J Antimicrob Chemother; 2008 Jan; 61(1):163-8. PubMed ID: 17967852
[TBL] [Abstract][Full Text] [Related]
11. In vitro evaluation of antibiotics' combinations for empirical therapy of suspected methicillin resistant Staphylococcus aureus severe respiratory infections.
Drago L; De Vecchi E; Nicola L; Gismondo MR
BMC Infect Dis; 2007 Sep; 7():111. PubMed ID: 17888153
[TBL] [Abstract][Full Text] [Related]
12. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia.
Sakoulas G; Gold HS; Cohen RA; Venkataraman L; Moellering RC; Eliopoulos GM
J Antimicrob Chemother; 2006 Apr; 57(4):699-704. PubMed ID: 16464892
[TBL] [Abstract][Full Text] [Related]
13. Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 1997 Aug; 46(33):765-6. PubMed ID: 9272582
[TBL] [Abstract][Full Text] [Related]
14. Multidrug and vancomycin resistance among clinical isolates of
Olufunmiso O; Tolulope I; Roger C
Afr Health Sci; 2017 Sep; 17(3):797-807. PubMed ID: 29085408
[TBL] [Abstract][Full Text] [Related]
15. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group.
Smith TL; Pearson ML; Wilcox KR; Cruz C; Lancaster MV; Robinson-Dunn B; Tenover FC; Zervos MJ; Band JD; White E; Jarvis WR
N Engl J Med; 1999 Feb; 340(7):493-501. PubMed ID: 10021469
[TBL] [Abstract][Full Text] [Related]
16. Optimal therapy for methicillin-resistant Staphylococcus aureus pneumonia: what is the best dosing regimen?
Rello J; Mallol J
Chest; 2006 Oct; 130(4):938-40. PubMed ID: 17035421
[No Abstract] [Full Text] [Related]
17. Clinical implications of vancomycin heteroresistant and intermediately susceptible Staphylococcus aureus.
Gomes DM; Ward KE; LaPlante KL
Pharmacotherapy; 2015 Apr; 35(4):424-32. PubMed ID: 25884530
[TBL] [Abstract][Full Text] [Related]
18. Treatment of methicillin-resistant Staphylococcus aureus in neonatal mice: lysostaphin versus vancomycin.
Placencia FX; Kong L; Weisman LE
Pediatr Res; 2009 Apr; 65(4):420-4. PubMed ID: 19127212
[TBL] [Abstract][Full Text] [Related]
19. Effect of vancomycin therapy for osteomyelitis on colonization by methicillin-resistant Staphylococcus aureus: lack of emergence of glycopeptide resistance.
Bernard L; Vaudaux P; Vuagnat A; Stern R; Rohner P; Pittet D; Schrenzel J; Hoffmeyer P;
Infect Control Hosp Epidemiol; 2003 Sep; 24(9):650-4. PubMed ID: 14510246
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus bacteremia with the addition of rifampin to daptomycin.
Ahmad NM; Rojtman AD
Ann Pharmacother; 2010 May; 44(5):918-21. PubMed ID: 20354160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
